WO2009128661A3 - 신규 벤조옥사진 벤즈이미다졸 유도체, 이를 포함하는 약학 조성물 및 이의 용도 - Google Patents
신규 벤조옥사진 벤즈이미다졸 유도체, 이를 포함하는 약학 조성물 및 이의 용도 Download PDFInfo
- Publication number
- WO2009128661A3 WO2009128661A3 PCT/KR2009/001977 KR2009001977W WO2009128661A3 WO 2009128661 A3 WO2009128661 A3 WO 2009128661A3 KR 2009001977 W KR2009001977 W KR 2009001977W WO 2009128661 A3 WO2009128661 A3 WO 2009128661A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- benzimidazole derivative
- pharmaceutical composition
- same
- benzoxazine benzimidazole
- novel benzoxazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009236824A AU2009236824B2 (en) | 2008-04-18 | 2009-04-16 | A novel benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof |
EP09733372.8A EP2264031B1 (en) | 2008-04-18 | 2009-04-16 | A novel benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof |
US12/934,638 US8362012B2 (en) | 2008-04-18 | 2009-04-16 | Benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof |
CA2719515A CA2719515C (en) | 2008-04-18 | 2009-04-16 | A novel benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof |
ES09733372.8T ES2539290T3 (es) | 2008-04-18 | 2009-04-16 | Un derivado novedoso de benzoxazina bencimidazol, una composición farmacéutica que comprende el mismo y su uso |
JP2011504927A JP5372138B2 (ja) | 2008-04-18 | 2009-04-16 | 新規ベンゾオキサジンベンズイミダゾール誘導体、これを含む薬学組成物およびこの用途 |
CN200980112215.XA CN101983197B (zh) | 2008-04-18 | 2009-04-16 | 新型苯并噁嗪苯并咪唑衍生物、含有该衍生物的药物组合物及其用途 |
NZ587771A NZ587771A (en) | 2008-04-18 | 2009-04-16 | Novel benzoxazine benzimidazole derivatives, pharmaceutical composition comprising same, and a use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20080036301 | 2008-04-18 | ||
KR10-2008-0036301 | 2008-04-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009128661A2 WO2009128661A2 (ko) | 2009-10-22 |
WO2009128661A3 true WO2009128661A3 (ko) | 2010-01-21 |
Family
ID=41199581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/001977 WO2009128661A2 (ko) | 2008-04-18 | 2009-04-16 | 신규 벤조옥사진 벤즈이미다졸 유도체, 이를 포함하는 약학 조성물 및 이의 용도 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8362012B2 (ko) |
EP (1) | EP2264031B1 (ko) |
JP (1) | JP5372138B2 (ko) |
KR (1) | KR101252334B1 (ko) |
CN (1) | CN101983197B (ko) |
AU (1) | AU2009236824B2 (ko) |
CA (1) | CA2719515C (ko) |
ES (1) | ES2539290T3 (ko) |
MY (1) | MY152022A (ko) |
NZ (1) | NZ587771A (ko) |
TW (1) | TWI395747B (ko) |
WO (1) | WO2009128661A2 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101293384B1 (ko) * | 2010-10-13 | 2013-08-05 | 주식회사 대웅제약 | 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도 |
WO2016020295A1 (en) | 2014-08-04 | 2016-02-11 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
AU2020405446A1 (en) | 2019-12-20 | 2022-05-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
EP4126874A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
WO2021198956A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
CN113234036B (zh) * | 2021-05-12 | 2023-07-14 | 斯莱普泰(上海)生物医药科技有限公司 | Nmda受体拮抗剂及其用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004035549A1 (en) * | 2002-10-17 | 2004-04-29 | Amgen Inc. | Benzimidazole derivatives and their use as vanilloid receptor ligands |
US20060116368A1 (en) * | 2004-11-29 | 2006-06-01 | Calvo Raul R | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6723730B2 (en) | 2000-07-20 | 2004-04-20 | Neurogen Corporation | Capsaicin receptor ligands |
AU2001278821A1 (en) | 2000-08-21 | 2002-03-04 | Pacific Corporation | Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same |
GB0105895D0 (en) | 2001-03-09 | 2001-04-25 | Smithkline Beecham Plc | Novel compounds |
JP4205430B2 (ja) | 2001-03-26 | 2009-01-07 | ノバルティス アクチエンゲゼルシャフト | 疼痛を治療するための、バニロイド受容体アンタゴニストとして、使用するための縮合ピリジン誘導体 |
GB0110901D0 (en) | 2001-05-02 | 2001-06-27 | Smithkline Beecham Plc | Novel Compounds |
US20040259875A1 (en) | 2001-07-31 | 2004-12-23 | Takeshi Yura | Amine derivatives |
PE20030417A1 (es) | 2001-09-13 | 2003-08-06 | Smithkline Beecham Plc | Derivados de urea como antagonistas del receptor vainilloide |
EP1437344A4 (en) | 2001-09-28 | 2006-09-20 | Takeda Pharmaceutical | BENZOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE |
JP2003192587A (ja) | 2001-12-26 | 2003-07-09 | Bayer Ag | 尿素誘導体 |
TW200406390A (en) | 2002-01-17 | 2004-05-01 | Neurogen Corp | Substituted quinazolin-4-ylamine analogues |
DE60325025D1 (de) | 2002-02-15 | 2009-01-15 | Glaxo Group Ltd | Modulatoren des vanilloidrezeptors |
ES2319886T3 (es) | 2002-02-20 | 2009-05-14 | Abbott Laboratories | Compuestos azabiciclicos condensados que inhiben el sutipo 1 del receptor valinoide (vr1). |
GB0206876D0 (en) | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
CA2486092A1 (en) | 2002-05-17 | 2003-11-27 | Janssen Pharmaceutica N.V. | Aminotetralin-derived urea modulators of vanilloid vr1 receptor |
CA2486376A1 (en) | 2002-05-22 | 2003-12-04 | Amgen Inc. | Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain |
CA2491079C (en) | 2002-06-28 | 2011-10-04 | Donald J. Kyle | Therapeutic piperazine derivatives useful for treating pain |
JP4555082B2 (ja) | 2002-08-08 | 2010-09-29 | アムジエン・インコーポレーテツド | バニロイド受容体リガンドおよびそれの治療での使用 |
GB0223730D0 (en) | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
KR100556158B1 (ko) | 2002-10-17 | 2006-03-06 | (주) 디지탈바이오텍 | 신규 엔-하이드록시 티오우레아, 우레아 및 아미드계화합물 및 이를 함유하는 약제학적 조성물 |
JP2006515846A (ja) | 2002-12-13 | 2006-06-08 | ニューロジェン・コーポレーション | カプサイシン受容体モジュレーターとしての2−置換キナゾリン−4−イルアミン類似体 |
US6933311B2 (en) | 2003-02-11 | 2005-08-23 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
EP1493438A1 (en) | 2003-07-03 | 2005-01-05 | Bayer HealthCare AG | Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states |
AU2004257289A1 (en) | 2003-07-16 | 2005-01-27 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
JP2007510706A (ja) | 2003-11-10 | 2007-04-26 | メルク シャープ エンド ドーム リミテッド | 痛みを治療するためのバニロイド−1受容体アンタゴニストとしての、置換された含窒素六員アミノ複素環 |
WO2006006740A1 (ja) | 2004-07-14 | 2006-01-19 | Japan Tobacco Inc. | 3−アミノベンズアミド化合物及びバニロイド受容体1型(vr1)活性阻害剤 |
CA2571133C (en) * | 2004-07-15 | 2011-04-19 | Japan Tobacco Inc. | Fused benzamide compound and vanilloid receptor 1 (vr1) activity inhibitor |
US7875627B2 (en) | 2004-12-07 | 2011-01-25 | Abbott Laboratories | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof |
KR20060087386A (ko) * | 2005-01-28 | 2006-08-02 | 주식회사 대웅제약 | 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물 |
KR101099303B1 (ko) * | 2005-01-28 | 2011-12-26 | 주식회사 대웅제약 | 신규한 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물 |
MX2007013931A (es) | 2005-05-12 | 2008-01-11 | Amgen Inc | Agentes antipireticos contra incrementos en la temperatura corporal inducidos por antagonista del receptor vainilloide 1. |
WO2007067619A2 (en) | 2005-12-08 | 2007-06-14 | Amphora Discovery Corporation | Certain chemical entities, compositions, and methods for modulating trpv1 |
WO2007067757A2 (en) | 2005-12-08 | 2007-06-14 | Amphora Discovery Corporation | Certain chemical entities, compositions, and methods for modulating trpv1 |
AR058705A1 (es) | 2005-12-23 | 2008-02-20 | Astrazeneca Ab | Compuestos de bencimidazol como inhibidores del receptor vaniloide 1 (vr1) |
JP4086895B2 (ja) * | 2005-12-28 | 2008-05-14 | 日本たばこ産業株式会社 | 3,4−ジヒドロベンゾオキサジン化合物及びバニロイド受容体1型(vr1)活性阻害剤 |
TW200738232A (en) | 2006-01-31 | 2007-10-16 | Alcon Mfg Ltd | Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma |
US7951829B2 (en) * | 2006-05-03 | 2011-05-31 | Janssen Pharmaceutica Nv | Benzimidazole modulators of VR1 |
EP1889837A1 (en) | 2006-07-10 | 2008-02-20 | Pharmeste S.r.l. | VR1 vanilloid receptor antagonists with a iononic substructure |
CN101490037B (zh) * | 2006-07-11 | 2013-06-12 | 大熊制药株式会社 | 联芳基苯并咪唑衍生物以及包含该衍生物的药物组合物 |
CA2656875C (en) | 2006-07-11 | 2011-09-06 | Pfizer Inc. | Substituted n-bicyclicalkyl bicyclic carboxyamide compounds |
TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
KR101293384B1 (ko) * | 2010-10-13 | 2013-08-05 | 주식회사 대웅제약 | 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도 |
-
2009
- 2009-04-16 CA CA2719515A patent/CA2719515C/en active Active
- 2009-04-16 WO PCT/KR2009/001977 patent/WO2009128661A2/ko active Application Filing
- 2009-04-16 US US12/934,638 patent/US8362012B2/en active Active
- 2009-04-16 NZ NZ587771A patent/NZ587771A/en not_active IP Right Cessation
- 2009-04-16 AU AU2009236824A patent/AU2009236824B2/en not_active Ceased
- 2009-04-16 JP JP2011504927A patent/JP5372138B2/ja active Active
- 2009-04-16 MY MYPI20104390 patent/MY152022A/en unknown
- 2009-04-16 CN CN200980112215.XA patent/CN101983197B/zh active Active
- 2009-04-16 EP EP09733372.8A patent/EP2264031B1/en active Active
- 2009-04-16 ES ES09733372.8T patent/ES2539290T3/es active Active
- 2009-04-16 KR KR1020090033268A patent/KR101252334B1/ko active IP Right Grant
- 2009-04-17 TW TW098112800A patent/TWI395747B/zh not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004035549A1 (en) * | 2002-10-17 | 2004-04-29 | Amgen Inc. | Benzimidazole derivatives and their use as vanilloid receptor ligands |
US20060116368A1 (en) * | 2004-11-29 | 2006-06-01 | Calvo Raul R | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor |
Non-Patent Citations (3)
Title |
---|
OGNYANOV, V.I. ET AL.: "Design of Potent, Orally Available Antagonists of the Transient Receptor Potential Vanilloid 1. Structure-Activity Relationships of 2-Piperazin-1-yl-1·H- benzimidazoles", JOURNAL OF MEDICINAL CHEMISTRY, 2006, pages 3719 - 3742, XP008140456 * |
See also references of EP2264031A4 * |
SHAO, B. ET AL.: "4-(2-Pyridyl)piperazine-l-benzimidazoles as potent TRPV1 antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, pages 719 - 723, XP027388643 * |
Also Published As
Publication number | Publication date |
---|---|
TW200948807A (en) | 2009-12-01 |
AU2009236824A2 (en) | 2010-10-28 |
KR101252334B1 (ko) | 2013-04-08 |
US8362012B2 (en) | 2013-01-29 |
CN101983197A (zh) | 2011-03-02 |
AU2009236824B2 (en) | 2012-02-16 |
JP2011518152A (ja) | 2011-06-23 |
EP2264031A4 (en) | 2012-06-13 |
KR20090110792A (ko) | 2009-10-22 |
US20110086849A1 (en) | 2011-04-14 |
WO2009128661A2 (ko) | 2009-10-22 |
AU2009236824A1 (en) | 2009-10-22 |
TWI395747B (zh) | 2013-05-11 |
CN101983197B (zh) | 2015-04-22 |
MY152022A (en) | 2014-08-15 |
EP2264031A2 (en) | 2010-12-22 |
CA2719515C (en) | 2013-11-05 |
JP5372138B2 (ja) | 2013-12-18 |
EP2264031B1 (en) | 2015-04-15 |
NZ587771A (en) | 2011-05-27 |
CA2719515A1 (en) | 2009-10-22 |
ES2539290T3 (es) | 2015-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012032209A3 (es) | Uso de un agonista de trpm8 para la elaboración de un medicamento para el tratamiento de xeroftalmia, sequedad vaginal y síndrome de la boca seca y uso de un antagonista de trpm8 para la elaboración de un medicamento pra el tratamiento de la epífora. | |
MX2010004281A (es) | Composiciones y metodos para el tratamiento de la retinopatia diabetica. | |
GB0906579D0 (en) | Pharmaceuticals, compositions and methods of making and using the same | |
WO2008008852A3 (en) | Cxcr4 antagonists including heteroatoms for the treatment of medical disorders | |
AU2011234398A8 (en) | Novel NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | |
WO2011041729A3 (en) | Compounds as lysophosphatidic acid receptor antagonists | |
CL2012001464A1 (es) | Compuestos derivados de (2-amino-5,5-difluor-5,6-dihidro-4h-[1,3]oxazin-4-il)-fenilamida, inhibidores bace1 y/o bace2; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento terapeutico y/o profilactico de enfermedades tales como alzheimer y diabetes. | |
IL225198A (en) | Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes | |
MX2011008450A (es) | Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos. | |
WO2010077883A3 (en) | Antagonists of lysophosphatidic acid receptors | |
WO2009153496A3 (fr) | Composes agonistes ppar, preparation et utilisations pour le traitement du diabete et/ou des dyslipidemies | |
WO2009128661A3 (ko) | 신규 벤조옥사진 벤즈이미다졸 유도체, 이를 포함하는 약학 조성물 및 이의 용도 | |
ATE533762T1 (de) | Chinolin- oder isochinolinsubstituierte p2x7- antagonisten | |
WO2010141761A3 (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
WO2011041461A3 (en) | Polycyclic compounds as lysophosphatidic acid receptor antagonists | |
CL2008000690A1 (es) | Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras. | |
WO2010039977A3 (en) | Heteroaryl antagonists of prostaglandin d2 receptors | |
WO2008148074A3 (en) | Inhibitors of mtor and methods of treatment using same | |
WO2009109613A3 (en) | 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 | |
WO2009109616A3 (en) | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40 | |
MY150823A (en) | Alkaloid aminoester derivatives and medicinal composition thereof | |
WO2009109654A8 (en) | 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1 | |
EP2438923A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF OBESITY-RELATED DISORDERS MEDIATED BY AMPK ACTIVATION AND THE ACTIVE INGREDIENTS OF WHICH HAVE 2,5-BIS-ARYL-3,4-DIMETHYLTETRAHYDROFURAN LIGNANS | |
ECSP088939A (es) | Carboxamidas sustituidas como antagonistas del receptor metabotropico del grupo i | |
WO2009156680A3 (fr) | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition pharmaceutique la contenant et son utilisation dans le traitement des troubles cognitifs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980112215.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09733372 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 587771 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009733372 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3443/KOLNP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PI 2010004390 Country of ref document: MY |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011504927 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2719515 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009236824 Country of ref document: AU Ref document number: 12010502174 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2009236824 Country of ref document: AU Date of ref document: 20090416 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12934638 Country of ref document: US |